Anti‐annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody | Zendy

Matsuda Juzo | Zendy; Saitoh Noriko | Zendy; Gohchi Kengo | Zendy; Gotoh Moritaka | Zendy; Tsukamoto And Miyo | Zendy

Premium

Anti‐annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody

Author(s) -

Matsuda Juzo,

Saitoh Noriko,

Gohchi Kengo,

Gotoh Moritaka,

Tsukamoto And Miyo

Publication year - 1994

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.2830470112

Subject(s) - lupus anticoagulant , anticardiolipin antibodies , medicine , autoantibody , antibody , systemic lupus erythematosus , immunology , thrombosis , antiphospholipid syndrome , connective tissue disease , systemic disease , systemic lupus , anticoagulant , autoimmune disease , immunopathology , disease

We investigated anti‐annexin V antibody (aANX) in patients with systemic lupus erythe‐matosus (SLE), and correlated to positivity with lupus anticoagulant (LA)/anticardiolipin antibody (aCL). aANX was positive in 12/47 SLE patients (26%), including 7 with β 2 ‐glycoprotein 1 (GPl)‐dependent aANX. The positivity of aANX was higher in patients with aCL (19%) and LA/aCL (50%) than in those without LA/aCL (10%). From these results, it is concluded that aANX is an autoantibody closely related to LA/aCL, and can be a possible new risk marker for thrombosis. © 1994 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research